Future Products


Aquila continues to work with it research partners to develop new assays using its hydrogel. This includes work with an aquaculture research institute in New Zealand and Canadian research groups developing water monitoring tests and STI tests.

Aquila is actively seeking additional collaborations for new targets. Aquila has done proof of principal test development for the following disease targets:

  1. Herpes simplex virus 1 & 2 (HSV-1 and HSV-2) from raw genital swabs (published in Lab Chip 7; 12: 1664-1671 (2012)) - STI Application
  2. FGFR2 and BK virus from raw urine (BK virus) or purified DNA (FGFR2) (published in Anal Chem 82; 18: 8079-8087 (2010)) - Cancer and transplant application
  3. Mycoplasma homonis and ureaplasma urealyticum from raw urine (published in Lab Chip 13; 13: 2576-2584 (2013)) - STI Application
  4. Blood group antigens (Rh, MNS, Duffy, Kell, Kidd, HPA-1a/1b) from plasma, serum and whole blood (unpublished) - Transfusion medicine application
  5. Ostreid Herpes Virus from water and shellfish tissue (unpublished) – Aquaculture application
  6. Cyanobacteria (blue green algae) from water (unpublished)
  7. Porcine circovirus 2 (PCV2) and porcine respiratory and reproductive syndrom virus (PRRSV) from whole blood (meeting abstract) – Ag. application
  8. Mycoplasma bovis, bovine viral diarrheal virus (BVDV), Histophilus somni from whole blood (meeting poster) – Ag. application
  9. P450 CYP3A5 (tamoxifen drug metabolism) in whole blood (unpublished) - cancer application
  10. Vibrio cholera in water (unpublished) - Tropical disease application
  11. FGFR2 from buccal (cheek) swabs (published in J Mol Diagn 16; 5: 550-557 (2014) - Cancer application
  12. African Swine Fever Virus (ASFV) and Capriopoxvirus from whole blood (unpublished) - Zoonotic animal disease application

 

Related Links

4-034 National Institute for Nanotechnology, 11421 Saskatchewan Drive, Edmonton, Alberta, Canada   T6G 2M9

   Subscribe to our newsletter